title: Improvement in vulvar vestibulitis with montelukast.
abstract: OBJECTIVE
  To determine if montelukast treatment improves symptoms in patients with vulvar vestibulitis.
  
  
  METHODS
  We administered montelukast to a series of patients with vestibulitis seen at the Pennsylvania State University Vulvodynia Clinic over a period of 2.5 years. We reviewed outcomes using a scoring scheme to quantify signs and symptoms, before and after treatment, in 29 montelukast-treated subjects and 18 subjects in a comparison group treated with standard therapies.
  
  
  RESULTS
  Subjects treated with montelukast showed an average of 52% in improvement in symptoms as compared to a 15% improvement in the controls (p < 0.0001).
  
  
  CONCLUSIONS
  Montelukast is a viable treatment option for women with vulvar vestibulitis. This finding implies that leukotrienes have a role in the pathophysiology of vulvar vestibulitis.
authors.affiliation: Department of Obstetrics and Gynecology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
authors.forename: Neha
authors.initials: N
authors.lastname: Kamdar
authors.forename: Laura
authors.initials: L
authors.lastname: Fisher
authors.forename: Colin
authors.initials: C
authors.lastname: MacNeill
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008875:Middle Aged; D011804:Quinolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D013440:Sulfides; D016896:Treatment Outcome; D054515:Vulvar Vestibulitis / Q000188:drug therapy*
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast